he AMDA was saddened to learn of the sudden passing of Henri Termeer, former CEO of Genzyme. We have known

Excerpt . . . . CRANBURY, N.J., May 15, 2017 —Amicus Therapeutics today announced positive functional data from initial patients

The AMDA is excited to announce that the 2017 PCMA of Texas Pull for Pompe will take place on Saturday,

The seventh annual AMDA Research Grant (the 2016 Helen Walker Research Grant) was awarded to Dr. Frédéric Lofaso with the

Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease Cambridge, Mass. – November 4,

The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe Disease research. This

The IPA Board was provided with the following statement regarding Biomarin’s BMN-701 study. If you have any questions or concerns

Please visit the IPA website to view the statement: http://worldpompe.org/index.php/news/590-ipa-statement-on-biomarin-s-june-9th-announcement-it-will-seek-to-out-license-bmn-701

UPDATE: DVD recordings of the Conference are available for purchase through the AMDA.  The recordings include all presentations and Question

In recognition of the third annual International Pompe Day, and the 10 Year Anniversary of the approval of Myozyme, Genzyme

On the third annual International Pompe Day, the Pompe Community turned its attention to the importance of Early Diagnosis. For

In 2014, the Pompe Registry recognized and celebrated an important milestone: the 10-year anniversary of the Registry. Started in 2004

Results support beginning pivotal Phase 3 clinical trial in Q2 2016 PARIS—(BUSINESS WIRE)—Sanofi and its specialty care global business unit

The AMDA is excited to announce that “Inspired by Pompe—High Protein, Reduced Carb Cooking” Cookbooks are availble for sale. This

Reveglucosidase Alfa Trends Positive in Respiratory Muscle Strength and Endurance Endpoints in Patients Previously Treated With Enzyme Replacement Therapy SAN

The AMDA is excited to announce that the 2016 PCMA of Texas Pull for Pompe will take place on Saturday,

CRANBURY, N.J., Dec. 22, 2015 (GLOBE NEWSWIRE)—Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of rare and orphan diseases,

The sixth annual AMDA Research Grant (the 2015 Helen Walker Research Grant) was awarded to Dr. Rosa Puertollano and Dr.

The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe Disease research. This

News Archives

Post Categories